Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference Nanotech Investing
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML Nanotech Investing
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss Nanotech Investing
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 Nanotech Investing
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program Nanotech Investing
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Nanotech Investing
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29 Nanotech Investing
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 Nanotech Investing
